Abstract: A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.

Abstract: The present disclosure provides an ultrasonic-microwave synergistic extraction method of total saponins in beautiful millettia root, comprising the following steps: S1, material treatment, S2, cold soaking, S3 enzymatic hydrolysis, S4 extract extraction, and S5 ultrasonic-microwave synergistic extraction. The extraction method of the present disclosure extracts relatively high content of total saponins, and has relatively high yield of saponins and low content of impurities, and each step acts synergistically to solve the problems of relatively low total saponin content, more impumayrities and bubbling in the extraction process.

Abstract: Disclosed herein, inter alia, are silicon containing detectable compounds and methods of use thereof.

Abstract: Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory disease, sexually transmitted bacterial infections, and some bioterror bacteria, including, for example, plague, tularemia and post-inhalation anthrax. Also disclosed herein are new salts and polymorphs of cethromycin for the treatment of inflammatory diseases, including, for example, pelvic inflammatory disease, and peptic ulcer disease.

Abstract: The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided.

Abstract: A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Za, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.

Abstract: The present invention relates to furazidin for vaginal use in the treatment of a bacterial vaginal infection. Preferably, the bacterial vaginal infection is caused by Gardnerella vaginalis and/or Atopobium vaginae bacteria.

Abstract: The present disclosure provides a siRNA for inhibiting the expression of apolipoprotein C3 (ApoC3) gene, and a pharmaceutical composition and a conjugate comprising the siRNA; wherein each nucleotide in the siRNA is independently a modified nucleotide, and the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A, the nucleotide sequence A having the same length as the nucleotide sequence as represented by SEQ ID NO:1 with no more than 3 nucleotide differences; the antisense strand comprises a nucleotide sequence B, the nucleotide sequence B having the same length as the nucleotide sequence as represented by SEQ ID NO:2 with no more than 3 nucleotide differences.

Abstract: The present invention relates to a Bifidobacterium bifidum inducing regulatory T cells (Treg), a polysaccharide derived from Bifidobacterium bifidum, and a probiotic strain producing a polysaccharide and, more particularly, a polysaccharide containing ?-1-6-glucan as an effective ingredient, a probiotic strain producing ?-1-6-glucan, a food comprising the polysaccharide or strain as an effective ingredient for alleviation of immune disease or inflammatory disease, a therapeutic agent comprising the polysaccharide or strain as an effective ingredient for alleviation of immune disease or inflammatory disease, a method for preparing induced regulatory T cells (iTreg) by treatment with the polysaccharide or strain, and a cell therapy product for prevention or treatment of immune disease or inflammatory disease, comprising the induced regulatory T cells prepared by the method.

Abstract: This specification discloses process for obtaining maltodextrin having DE between 17 and 19.9 and the maltodextrins obtained from the process. The disclosed maltodextrins can be provided as a powder or in shelf stable liquid form. The disclose maltodextrins have a polysaccharide profile similar to those observed for prior art maltodextrins, but make maltodextrin solutions having a high solids content, but reduced viscosity compared to prior art maltodextrins, on equivalent solids-in-solution basis. The process combines adds an alpha-amylase and a pullulanase enzyme to a polysaccharide mixture during a saccharification step. The disclosed maltodextrins make solutions at 50° C. and greater than 65% on a solids dry solids basis having a viscosity between 5,000 and 12,000 cP and having a water activity of less than 0.80.

Abstract: A method is provided for the post-treatment of nanoporous celluloses with an eye to scale up to plant operation wherein recycling and recovery of reagents is crucial in the efficient and cost effective operation of a full-scale plant. The instant method includes diminishing the alkali (e.g., sodium hydroxide) concentration of the treatment solution by converting it to a salt (e.g., a sodium salt).

Abstract: The present application belongs to a technical field of modifying natural polymer materials, provides a high-viscosity lithium carboxymethyl cellulose and preparation method therefor and application thereof. Raw materials are fed into a reactor, and the high-viscosity lithium carboxymethyl cellulose is prepared through an alkalization reaction, an etherification reaction, an acidification reaction and a substitution reaction. The prepared high-viscosity lithium carboxymethyl cellulose can be used for preparing a negative electrode plate of a lithium-ion battery. Compared with the existing lithium carboxymethyl cellulose, the high-viscosity lithium carboxymethyl cellulose provided by the present application can not only reduce an application amount in preparing a negative electrode plate of a lithium-ion battery so as to save a using cost, but also promote an electrochemical performance of the material in combination with a sodium lignin sulfonate.

Abstract: A cellulose derivative having a long-chain organic group having 5 or more carbon atoms and a short-chain organic group having 4 or less carbon atoms which are introduced by use of hydroxy groups of a cellulose, and including a crystal structure derived from a cellulose derivative portion to which the short-chain organic group is linked, wherein an average number of hydroxy groups per glucose unit is of 1.0 or less.

Abstract: Recent advancements in LNA oligonucleotides include the use of amine linkers to link an LNA antisense oligonucleotide to a conjugate group. For example please see WO2014/I18267. The present invention originates from the identification of a problem when de-protecting LNA oligonucleotides which comprise an aliphatic amine group and DMF protected LNA G nucleoside, which results in the production of a +28 Da impurity. This problem is solved by using acyl protection groups on the exocyclic nitrogen of the LNA-G residue, rather than the standard DMF protection group.

Abstract: Selectively controllable cleavable linkers include electrochemically-cleavable linkers, photolabile linkers, thermolabile linkers, chemically-labile linkers, and enzymatically-cleavable linkers. Selective cleavage of individual linkers may be controlled by changing local conditions. Local conditions may be changed by activating electrodes in proximity to the linkers, exposing the linkers to light, heating the linkers, or applying chemicals. Selective cleaving of enzymatically-cleavable linkers may be controlled by designing the sequences of different sets of the individual linkers to respond to different enzymes. Cleavable linkers may be used to attach polymers to a solid substrate. Selective cleavage of the linkers enables release of specific polymers from the solid substrate. Cleavable linkers may also be used to attach protecting groups to the ends of growing polymers. The protecting groups may be selectively removed by cleavage of the linkers to enable growth of specific polymers.

Abstract: A fine cellulose fiber in which when the fine cellulose fiber is formed into a dispersion, the dispersion has very high light transmittance and viscosity, and a method for producing the fine cellulose fiber. The fine cellulose fiber has a fiber width of 1 to 200 nm. A part of hydroxy groups of the cellulose fiber are substituted with a predetermine functional group to introduce an ester of phosphorus-oxo acid, and the introduction amount of the functional group is more than 2.0 mmol per 1 g of the cellulose fiber. For producing the fine cellulose fiber, to cellulose fiber is added a solution having a pH of less than 3.0 and including an additive (A) containing at least one of a phosphorus-oxo acid and a phosphorus-oxo acid metal salt and an additive (B) containing at least one of urea and a urea derivative, and the mixture is heated to perform fibrillation.

Abstract: Disclosed herein are immunogenic trehalose compounds and methods of use thereof, for example as vaccine adjuvants.

Abstract: Method for the production of a polyphenolic composition from barley malt, including the fundamental steps of: grinding of the malt grains and splitting into two portions, 20% and 80%; mixing each of the two portions with water to obtain an A mixture and a B mixture, the A mixture being prepared with the 20% portion to obtain a mixture of the malt in water at a final concentration between 9.5% and 20%, the B mixture being prepared with the 80% portion to obtain a mixture of the malt in water at a final concentration between 33% and 60%; thermal cycle; separation of the liquid component from the solid component; boiling of the liquid component and the addition of hops; rapid cooling of the wort; storage; in which said thermal cycle consists of a first phase and a second phase, in which the first phase applies to the 20% portion (Mixture A) and the second phase during which Mixture B is added to Mixture A.

Abstract: Compositions and compounds of nucleoside phosphoramidites and modified oligonucleotides, each comprising one or more charge-neutralizing moieties according to the formula V The nucleoside phosphoramidites permit facile attachment of the neutralizing moieties on the backbones of the modified oligonucleotides. The modified oligonucleotides can be used as therapeutic agents (i.e., oligotherapeutics) for the treatment of cancer, autoimmune disorders, genetic diseases, infectious diseases, neurological diseases, inflammatory diseases, metabolic diseases and others.